0I3Q.L - Corcept Therapeutics Incorporated

LSE - LSE Delayed price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 314.59%
S&P500 52-week change 36.21%
52-week high 330.09
52-week low 30.00
50-day moving average 322.10
200-day moving average 324.21

Share statistics

Avg vol (3-month) 3133
Avg vol (10-day) 393
Shares outstanding 5115.47M
Implied shares outstanding 6N/A
Float 882.99M
% held by insiders 111.59%
% held by institutions 183.62%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023

Profitability

Profit margin 22.84%
Operating margin (ttm)24.34%

Management effectiveness

Return on assets (ttm)11.59%
Return on equity (ttm)20.16%

Income statement

Revenue (ttm)413.82M
Revenue per share (ttm)3.86
Quarterly revenue growth (yoy)12.80%
Gross profit (ttm)396.47M
EBITDA 101.38M
Net income avi to common (ttm)94.3M
Diluted EPS (ttm)0.91
Quarterly earnings growth (yoy)-30.30%

Balance sheet

Total cash (mrq)465.06M
Total cash per share (mrq)4.58
Total debt (mrq)575k
Total debt/equity (mrq)0.11
Current ratio (mrq)6.77
Book value per share (mrq)4.90

Cash flow statement

Operating cash flow (ttm)111.03M
Levered free cash flow (ttm)105.44M